| Zeit | Aktuelle Nachrichten Sprache: 
Alle DE EN  | Leser | Medien | ||
|---|---|---|---|---|---|
| RHINO BIOTECH Aktie jetzt für 0€ handeln | 
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,79 | 0,00 % | Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) | ||
| PRAXIS PRECISION MEDICINES | 182,05 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen  | |
| RECURSION PHARMACEUTICALS | 5,430 | 0,00 % | Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? | ||
| PRELUDE THERAPEUTICS | 3,960 | 0,00 % | Prelude Therapeutics shifts focus to JAK2 and KAT6A programs | ||
| PHIO PHARMACEUTICALS | 1,870 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds | King of Prussia, Pennsylvania--(Newsfile Corp. - November 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary... ► Artikel lesen  | |
| DYNE THERAPEUTICS | 24,100 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 -    WALTHAM, Mass., Aug.... ► Artikel lesen  | |
| ADMA BIOLOGICS | 15,355 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase  2Q 2025 Adjusted... ► Artikel lesen  | |
| IMMUNOME | 17,060 | 0,00 % | Immunome: Neuer ADC-Wirkstoff zeigt Potenzial gegen Krebs-Resistenzen | ||
| QIAGEN | 39,340 | -0,32 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen  | |
| IMMUNOVANT | 23,770 | 0,00 % | Immunovant gains amid takeover speculation | ||
| BIONTECH | 90,20 | -0,06 % | Innovation trifft Biotech: Dieses Unternehmen mischt Big Pharma mit smarter Wirkstoff-Revolution auf! | Anzeige / WerbungEine spannende Alternative zu Evotec, BioNTech und Co. ist BioNxt Solutions.
Das kanadisch-deutsche Unternehmen unterscheidet sich mit seinem Geschäftsmodell erfrischend... ► Artikel lesen  | |
| BEAM THERAPEUTICS | 24,265 | 0,00 % | Beam Therapeutics Inc. - 10-Q, Quarterly Report | ||
| VERA THERAPEUTICS | 25,930 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on October 6, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics... ► Artikel lesen  | |
| HARMONY BIOSCIENCES | 29,330 | 0,00 % | Earnings Preview For Harmony Biosciences | ||
| LENZ THERAPEUTICS | 27,920 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals  Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025  VIZZ is... ► Artikel lesen  |